

Qiu Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4865169/publications.pdf>

Version: 2024-02-01

128
papers

2,341
citations

394421

19
h-index

289244

40
g-index

134
all docs

134
docs citations

134
times ranked

2345
citing authors

#	ARTICLE	IF	CITATIONS
1	CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. <i>Journal of Dental Research</i> , 2022, 101, 206-215.	5.2	25
2	Regulating Fibrocartilage Stem Cells via TNF- α /Nf- κ B in TMJ Osteoarthritis. <i>Journal of Dental Research</i> , 2022, 101, 312-322.	5.2	21
3	First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness. <i>Clinical Oncology</i> , 2022, 34, e123-e129.	1.4	4
4	Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	3.2	4
5	Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1559-1566.	1.0	8
6	The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 453-453.	1.6	10
7	PK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. <i>Cell Death and Disease</i> , 2022, 13, 118.	6.3	23
8	Causal Association between Chronic Kidney Disease and Risk of 19 Site-Specific Cancers: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1233-1242.	2.5	4
9	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis. <i>Clinical Breast Cancer</i> , 2022, 22, e629-e635.	2.4	4
10	Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. <i>Immunotherapy</i> , 2022, 14, 459-473.	2.0	3
11	An observational study of dose-optimization for fruquintinib in elderly patients (pts) with metastatic colorectal cancer (mCRC) who had failed standard therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15560-e15560.	1.6	0
12	A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2610-2610.	1.6	0
13	Cost-effectiveness Analysis of Helicobacter pylori Eradication Therapy in First-Degree Relatives of Patients with Gastric Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 77-85.	1.8	7
14	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021, 21, 35.	2.6	7
15	Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 608375.	2.7	5
16	Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states. <i>Liver International</i> , 2021, 41, 1097-1104.	3.9	43
17	The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 582040.	2.8	5
18	Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326.	3.7	3

#	ARTICLE	IF	CITATIONS
19	First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. <i>Cancer Medicine</i> , 2021, 10, 3388-3402.	2.8	5
20	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 559-568.	8.1	121
21	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021, 22, 977-990.	10.7	459
22	The role of non-apoptotic cell death in the treatment and drug-resistance of digestive tumors. <i>Experimental Cell Research</i> , 2021, 405, 112678.	2.6	13
23	Impact of Coronavirus Disease 2019 on Clinical Characteristics in Patients With Lung Cancer: A Large Single-Centre Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 693002.	2.8	9
24	Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer. <i>Lancet Oncology</i> , 2021, 22, e358-e368.	10.7	133
25	Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 391.	4.4	34
26	miR-26a enhances colorectal cancer cell growth by targeting RREB1 deacetylation to activate AKT-mediated glycolysis. <i>Cancer Letters</i> , 2021, 521, 1-13.	7.2	15
27	Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	1
28	Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. <i>Advances in Therapy</i> , 2021, 38, 5662-5670.	2.9	3
29	Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte-Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 690874.	3.5	2
30	Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review. <i>Frontiers in Public Health</i> , 2021, 9, 768765.	2.7	2
31	Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 692005.	2.8	0
32	Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective. <i>Clinical and Translational Oncology</i> , 2020, 22, 103-110.	2.4	9
33	Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 337-343.	2.4	6
34	S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 133-138.	1.4	4
35	First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis. <i>Breast Cancer</i> , 2020, 27, 399-404.	2.9	4
36	Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. <i>European Journal of Cancer Care</i> , 2020, 29, e13196.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of Capecitabine+ Irinotecan Versus Leucovorin+ Fluorouracil+ Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. <i>Clinical Therapeutics</i> , 2020, 42, 2148-2158.e2.	2.5	7
38	Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells. <i>FASEB Journal</i> , 2020, 34, 11185-11199.	0.5	8
39	Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	3.2	20
40	Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. <i>Immunotherapy</i> , 2020, 12, 1021-1034.	2.0	3
41	Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives. <i>Frontiers in Oncology</i> , 2020, 10, 1336.	2.8	19
42	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 570268.	2.8	3
43	Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer. <i>Tumori</i> , 2020, 106, 400-405.	1.1	3
44	Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis. <i>Cancer Medicine</i> , 2020, 9, 5312-5319.	2.8	6
45	Development and validation of a nomogram for predicting overall survival of gastric cancer patients after D2R0 resection. <i>European Journal of Cancer Care</i> , 2020, 29, e13260.	1.5	8
46	Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. <i>Oncology Research and Treatment</i> , 2020, 43, 153-159.	1.2	6
47	LepR-Expressing Stem Cells Are Essential for Alveolar Bone Regeneration. <i>Journal of Dental Research</i> , 2020, 99, 1279-1286.	5.2	37
48	Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2020, 103, 104588.	1.5	14
49	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. <i>Oral Oncology</i> , 2020, 107, 104754.	1.5	7
50	Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4507-4507.	1.6	24
51	Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1189-1198.	2.4	42
52	national initiative in data science for health: an evaluation of the UK Farr Institute. <i>International Journal of Population Data Science</i> , 2020, 5, 1128.	0.1	4
53	An exploratory study of fruquintinib as second-line treatment for patients with advanced or metastatic biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4657-TPS4657.	1.6	0
54	An exploratory study of sorafenib plus toripalimab for unresectable hepatocellular carcinoma with portal vein tumor thrombus.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4658-TPS4658.	1.6	0

#	ARTICLE	IF	CITATIONS
55	<p>Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial</p>. Cancer Management and Research, 2020, Volume 12, 12919-12926.	1.9	6
56	Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial. Radiotherapy and Oncology, 2019, 141, 27-32.	0.6	7
57	Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiation Oncology, 2019, 14, 113.	2.7	14
58	Costâ€effectiveness analysis of cabozantinib as secondâ€line therapy in advanced hepatocellular carcinoma. Liver International, 2019, 39, 2408-2416.	3.9	25
59	Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer, 2019, 136, 98-101.	2.0	31
60	Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer, 2019, 130, 1-4.	2.0	57
61	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. Oncologist, 2019, 24, 591-e165.	3.7	11
62	Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis. Oral Oncology, 2019, 93, 15-20.	1.5	6
63	Factors related to the receipt of adjuvant therapy among patients with gastric cancer in Western China. European Journal of Cancer Care, 2019, 28, e13012.	1.5	1
64	Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis. Frontiers in Oncology, 2019, 9, 1357.	2.8	3
65	<p>Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer</p>. Cancer Management and Research, 2019, Volume 11, 10419-10426.	1.9	8
66	Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review. Frontiers in Oncology, 2019, 9, 1180.	2.8	2
67	Antitumor activity in colorectal cancer induced by hinokiflavone. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1571-1580.	2.8	17
68	Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal of Medical Economics, 2019, 22, 344-349.	2.1	34
69	Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.. Journal of Clinical Oncology, 2019, 37, e20674-e20674.	1.6	1
70	Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2019, 37, e15011-e15011.	1.6	0
71	OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open, 2018, 8, e020128.	1.9	11
72	Overcoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures. Nanoscale, 2018, 10, 5457-5465.	5.6	123

#	ARTICLE	IF	CITATIONS
73	Forty-nine cases of acute lymphoblastic leukaemia/lymphoma in pleural and pericardial effusions: A cytological-histological correlation. <i>Cytopathology</i> , 2018, 29, 172-178.	0.7	7
74	Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. <i>Clinical and Translational Oncology</i> , 2018, 20, 768-774.	2.4	6
75	Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer. <i>Medicine (United States)</i> , 2018, 97, e12601.	1.0	6
76	Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. <i>Cancer Management and Research</i> , 2018, Volume 10, 4065-4072.	1.9	7
77	Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial. <i>Bone and Joint Journal</i> , 2018, 100-B, 1025-1032.	4.4	33
78	LC-MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells. <i>Oncology Reports</i> , 2018, 40, 1026-1034.	2.6	12
79	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21154-e21154.	1.6	2
80	Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15565-e15565.	1.6	0
81	Quantification of skin stiffness in patients with systemic sclerosis using real-time shear wave elastography: a preliminary study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 118-125.	0.8	10
82	Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. <i>European Journal of Cancer Care</i> , 2017, 26, e12505.	1.5	13
83	Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. <i>Lung Cancer</i> , 2017, 110, 1-6.	2.0	14
84	Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1117-1124.	2.4	8
85	Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 493-498.	1.3	8
86	Lentiviral vector-mediated shRNAs targeting a functional isoform of the leptin receptor (Ob-Rb) inhibit cartilage degeneration in a rat model of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 1912-1921.	1.3	4
87	Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 361-368.	2.5	26
88	Addition of Docetaxel and/or Zoledronic Acid to Standard of Care for Hormone-naive Prostate Cancer: A Cost-effectiveness Analysis. <i>Tumori</i> , 2017, 103, 380-386.	1.1	12
89	MMHG: Multi-modal Hypergraph Learning for Overall Survival After D2 Gastrectomy for Gastric Cancer. , 2017, , .		2
90	A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15682-e15682.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study. <i>Oncotarget</i> , 2017, 8, 97890-97899.	1.8	5
92	Antitumor immunity induced by VE-cadherin modified DC vaccine. <i>Oncotarget</i> , 2017, 8, 67369-67379.	1.8	5
93	Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1978-1985.	2.8	13
94	Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites. <i>Oncology Reports</i> , 2016, 35, 1573-1581.	2.6	8
95	FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. <i>Digestive and Liver Disease</i> , 2016, 48, 1492-1497.	0.9	16
96	Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center. <i>Oncology Letters</i> , 2016, 11, 3501-3507.	1.8	2
97	Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 36060.	3.3	3
98	Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodigie and MPACT Trials. <i>Tumori</i> , 2016, 102, 294-300.	1.1	14
99	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. <i>Gastric Cancer</i> , 2016, 19, 245-254.	5.3	7
100	Efficacy and cost-effectiveness of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15622-e15622.	1.6	1
101	Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1-1.	1.6	1
102	Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. <i>Oncotarget</i> , 2016, 7, 7761-7772.	1.8	2
103	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	1.8	6
104	Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 5332.	3.3	19
105	Oxaliplatin plus fluorouracil/leucovorin or sorafneib as first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18270-e18270.	1.6	0
106	Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 853-859.	1.6	41
107	A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. <i>Liver International</i> , 2015, 35, 2147-2154.	3.9	38
108	A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. <i>Medical Oncology</i> , 2015, 32, 247.	2.5	4

#	ARTICLE	IF	CITATIONS
109	Livin modulates the apoptotic effects of vesicular stomatitis virus in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2015, 47, 1775-1782.	3.3	2
110	Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. <i>Medical Oncology</i> , 2015, 32, 121.	2.5	10
111	Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1082-1088.	1.0	16
112	Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study. <i>Cancer Biology and Therapy</i> , 2015, 16, 1577-1584.	3.4	16
113	Prognostic significance of protein kinase BAKT pathway in adult adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22229-e22229.	1.6	0
114	Rectal adenocarcinoma metastatic to the tonsil; PET-CT observations with pathological confirmation: A case report. <i>Oncology Letters</i> , 2014, 7, 153-155.	1.8	4
115	Acetyl-L-Carnitine for the Treatment of Peripheral Neuropathic Pain: a Systematic Review and Meta-Analysis. <i>Value in Health</i> , 2014, 17, A810.	0.3	1
116	Hydroxyethyl Starch And Hospitalized Mortality In Icu Patients With Diabetes: Database Study From A Chinese Tertiary Hospital. <i>Value in Health</i> , 2014, 17, A742-A743.	0.3	0
117	The Impact Of Diabetes On Mortality In Inpatients From Medical Department Of A Chinese Tertiary Hospital. <i>Value in Health</i> , 2014, 17, A742.	0.3	0
118	Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. <i>World Journal of Gastroenterology</i> , 2014, 20, 17976-17984.	3.3	11
119	Surgical treatment for large spontaneous basal ganglia hemorrhage: retrospective analysis of 253 cases. <i>British Journal of Neurosurgery</i> , 2013, 27, 617-621.	0.8	39
120	Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 754-758.	1.4	16
121	First-Line Irinotecan Combined with 5-Fluorouracil and Leucovorin for High-Grade Metastatic Gastrointestinal Neuroendocrine Carcinoma. <i>Tumori</i> , 2013, 99, 57-60.	1.1	10
122	The role of ultrasonography in the diagnosis of gluteal muscle contracture. <i>Skeletal Radiology</i> , 2011, 40, 215-221.	2.0	12
123	Clinical management of gastric cancer: results of a multicentre survey. <i>BMC Cancer</i> , 2011, 11, 369.	2.6	4
124	A Pilot Study of Irinotecan Combined with 5-Fluorouracil and Leucovorin for the Treatment of Chinese Patients with Locally Advanced and Metastatic Gastric Cancer. <i>Tumori</i> , 2009, 95, 432-437.	1.1	3
125	A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer. <i>Tumori</i> , 2009, 95, 432-7.	1.1	2
126	Nuclear Translocation of SMAD3 May Enhance the TGF- β 2/SMADS Pathway in High Glucose Circumstances. <i>Transplantation Proceedings</i> , 2006, 38, 2158-2160.	0.6	4

#	ARTICLE	IF	CITATIONS
127	Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. <i>International Journal of Cancer</i> , 2004, 112, 143-149.	5.1	31
128	Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. <i>Nature Medicine</i> , 2000, 6, 1160-1166.	30.7	224